Pancreatic cancer is the 10th most common type of cancer. In 2022, more than 2,400 new cases were diagnosed in the Czech Republic.
Approximately 2,100 patients will succumb to this disease, which is more than 87%. The main reason for the high percentage of deaths is the late diagnosis of this cancer, therefore Lipidica, a.s. is preparing the implementation of a study of the functional suitability of the lipidomic test LDPC called “Study of the clinical function of the medical device-software “Lipidica 1.0″ processing data from lipidomic analysis (LDPC) for pancreatic cancer screening”.
Approximately 400 participants will be assigned to the following groups:
The study is conducted in collaboration with CZECRIN, Masaryk Cancer Institute and 14 other large hospitals in the Czech Republic.
The study documentation is currently being reviewed by the ethics committees of the hospitals concerned and by the regulatory authority. In case of successful completion of the study, the test can be used in clinical practice to monitor people at risk.
CZECRIN Office
Faculty of Medicine, Masaryk University Department of Pharmacology LRI CZECRIN Kamenice 5,625 00 Brno, Česká Republika
Info@czecrin.cz Phone: +420 549 498 165 Phone: +420 725 828 348
